Cannabis Oil Did Not Meaningfully Reduce Pain in Nerve-Injury Patients, Rigorous Trial Finds

A well-designed triple-blind crossover randomized controlled trial in patients with traumatic brachial plexus injury demonstrates a statistically significant but clinically trivial one-point pain reduction with cannabis-based sublingual oil, while a modest sleep quality improvement warrants further investigation before any change in practice can be justified.

Why This Matters

Traumatic brachial plexus injury produces some of the most severe and treatment-resistant neuropathic pain encountered in clinical practice, and patients frequently ask about cannabis as an adjunct when standard pharmacotherapy falls short. The mechanistic rationale linking cannabinoid receptor modulation to neuropathic pain suppression is scientifically plausible, which makes rigorous clinical testing essential rather than optional. This trial is reportedly only the second randomized controlled trial to address cannabis in this specific population, making it a critical data point at a time when regulatory access to cannabis-based medicines is expanding across multiple jurisdictions.

Clinical Summary

Neuropathic pain following traumatic brachial plexus injury remains a major clinical challenge, with many patients experiencing inadequate relief from gabapentinoids, antidepressants, and opioid combinations. Researchers at Lerdsin General Hospital in Bangkok, Thailand conducted a prospective, triple-blind, two-period crossover RCT (published 2025) to determine whether sublingual cannabis oil containing up to 30 mg of THC per day, added to existing pain regimens, could produce clinically meaningful analgesia. The endocannabinoid system’s role in modulating pain signaling at both peripheral and central levels provided the biological rationale, and the crossover design was well suited to a population with stable, chronic pain where each patient could serve as their own control.

Among 28 analyzed patients, cannabis-based medicine produced a mean pain VAS reduction of 1.0 point compared to placebo, which reached statistical significance at a stringent threshold (99% CI: -0.03 to 2.1; p=0.01) but fell below the pre-specified minimum clinically important difference of 2 points. Neuropathic pain classification by the DN4 questionnaire was identical between arms (75% positive in both; OR 1, p>0.99). Sleep quality VAS favored cannabis with a mean difference of 1.5 points (p<0.001), though no MCID for sleep was pre-specified. Adverse events were limited to mild dizziness in four patients during the cannabis period. The authors concluded explicitly that cannabis-based medicine should not be added to standard pharmacotherapy for this indication, and they called for larger, longer, multicenter trials before any clinical recommendations can be made.

Dr. Caplan’s Take

This is exactly the kind of study the field needs more of: rigorous, pre-registered, appropriately blinded, and honest about what the numbers actually show. The investigators had every opportunity to frame a statistically significant result as a win, and instead they held themselves to the clinically meaningful threshold they set before enrollment began. That intellectual honesty matters, because patients with brachial plexus injuries who come to me asking about cannabis are typically at the end of their rope, and what they need is a truthful accounting of what the evidence supports rather than false hope dressed up in p-values.

In practice, when a patient with refractory nerve-injury pain asks about cannabis, I walk them through this kind of evidence: a real signal exists, but it is too small to justify adding cannabis to an already complex medication regimen based on current data. I focus on optimizing their existing pharmacotherapy, ensuring adequate gabapentinoid dosing, addressing sleep and mood comorbidities through validated approaches, and revisiting the conversation if stronger evidence emerges. The sleep quality finding is intriguing but not yet actionable as a standalone reason to prescribe.

Clinical Perspective

This trial sits at an important inflection point in the research arc for cannabinoids and neuropathic pain. It confirms that a measurable pharmacological effect exists in this population, consistent with broader literature showing modest cannabinoid effects on various neuropathic pain syndromes, but it also demonstrates that measurability and clinical meaningfulness are not the same thing. The failure to reach the 2-point MCID despite statistical significance underscores why pre-specified clinical thresholds are indispensable in pain research. For patient-facing recommendations, this study does not support adding cannabis-based medicine to existing regimens for brachial plexus injury pain. The sleep quality improvement, while statistically robust, lacks a defined clinical significance threshold and should not be extrapolated into a general sleep indication.

From a pharmacological standpoint, the THC dose ceiling of 30 mg per day is relatively modest, and clinicians should note that even at this dose, dizziness occurred in approximately 14% of participants during the active period. Drug interactions with gabapentinoids and tricyclic antidepressants, which are common in this population, were not reported in the available text but remain a relevant concern given overlapping CNS depression profiles. The single most actionable takeaway for clinicians right now is to ensure that standard neuropathic pain protocols are fully optimized before considering any adjunctive cannabis trial, and to set explicit outcome benchmarks with patients if such a trial is undertaken.

Study at a Glance

Study Type

Triple-blind, two-period crossover randomized controlled trial

Population

Adults with traumatic brachial plexus injury and refractory neuropathic pain (single center, Bangkok, Thailand)

Intervention

Sublingual cannabis oil (up to 30 mg THC/day) for 10 days, added to standard pharmacotherapy

Comparator

Identical placebo sublingual oil for 10 days

Primary Outcomes

Visual analog scale (VAS) for pain, with pre-specified MCID of 2 points

Sample Size

30 enrolled, 28 analyzed (93% retention)

Journal

Journal of Hand Surgery (Asian-Pacific Volume), 2025

Year

2025

DOI or PMID

Registration: TCTR20191106004

Funding Source

Thai Ministry of Public Health; no commercial conflicts reported

What Kind of Evidence Is This

This is a prospective, triple-blinded, two-period crossover placebo-controlled randomized controlled trial with pre-registration and a priori power calculation, representing Level 1 therapeutic evidence. The crossover design is a notable strength for a rare, stable-pain population, as each participant serves as their own control, but the most important inference constraint is the short 10-day treatment period per arm, which limits conclusions about sustained efficacy, tolerance development, or longer-term safety in a condition that requires chronic management.

How This Fits With the Broader Literature

The broader cannabinoid-neuropathic pain literature has generally shown small to modest analgesic effects, with systematic reviews such as those by Mücke et al. (2018) and Aviram and Samuelly-Leichtag (2017) reporting effect sizes that are statistically detectable but frequently fail to reach established clinical importance thresholds. This trial aligns with that pattern: a real but insufficient analgesic signal. It also echoes findings from the nabiximols literature in multiple sclerosis-related neuropathic pain, where initial statistical signals have not consistently translated into clinically meaningful relief across larger trials. The sleep quality finding is less well contextualized, as few cannabinoid trials in nerve-injury populations have reported sleep as a formal secondary outcome with validated instruments.

Common Misreadings

The most likely overinterpretation is citing the statistically significant pain result (p=0.01) as evidence that cannabis “works” for brachial plexus pain. It does not. The study’s own pre-specified threshold for clinical relevance was a 2-point VAS change, and the observed 1-point difference fell clearly below that bar. Statistical significance at a stringent confidence level reflects adequate power to detect a small effect, not that the effect is large enough to justify treatment. A secondary misreading involves treating the sleep quality improvement as a standalone reason to prescribe cannabis-based medicine; without an established MCID for that outcome, the clinical importance of a 1.5-point VAS difference for sleep remains genuinely uncertain.

Bottom Line

This well-conducted crossover RCT establishes that sublingual cannabis oil produces a detectable but clinically insufficient reduction in pain for patients with traumatic brachial plexus injury on standard pharmacotherapy. It does not support adding cannabis-based medicine to existing regimens for this indication. The sleep quality signal is worth investigating further but is not actionable in isolation. Larger, longer, multicenter trials are needed before any revision of clinical practice can be considered.

References

1. Triple-blind, two-period crossover RCT of cannabis-based medicine for traumatic brachial plexus injury pain. Journal of Hand Surgery (Asian-Pacific Volume), 2025. Trial registration: TCTR20191106004. Funded by the Thai Ministry of Public Health.
2. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 2018. DOI: 10.1002/14651858.CD012182.pub2.
3. Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician, 2017;20(6):E755-E796. PMID: 28934780.